Metabolic measure ranked best for multiple-disease risk
An insulin-response estimate scored 0.811 for distinguishing future multiple-disease cases from non-cases, outperforming eight other metabolic indices.
Paper by Qilong Zhai, Shasha Guo, Jialu Sun et al.

Our read
Biomarkers- Studied:
- Accepted, not yet published: cohort study of 375,790 UK Biobank participants, mean 13.74 years
- What changed:
- An insulin-response estimate distinguished future multiple-disease cases better than the other metabolic indices, scoring 0.811
- The catch:
- The analyses measured risk discrimination, not whether eGDR-guided care prevents multiple diseases
- In the record:
- The 104th paper on estimated glucose disposal rate with results in people; 145 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
The 375,790 UK Biobank participants in this prospective cohort study initially had no cardiovascular disease, type 2 diabetes or metabolic dysfunction-associated steatotic liver disease, a buildup of liver fat linked to metabolic problems. Over an average 13.74 years, 8,984 developed cardiovascular–liver–metabolic multimorbidity, meaning combinations of these diseases.
The researchers compared nine metabolic indices. Estimated glucose disposal rate, an estimate of how well the body responds to insulin, best distinguished future cases from non-cases. Insulin is a hormone that controls blood sugar. Each increase of one standard deviation—a measure of variation among participants—was associated with a 66% lower relative risk of developing multiple diseases. Higher values were also linked to lower risks of progressing from no disease to one disease and then to multiple diseases.
Why it matters
The accumulation of cardiovascular, liver and metabolic diseases matters for health in later life. The authors suggest routine metabolic measures may help identify unfavorable risk profiles before multiple diseases develop.
Caveats
Other health differences could have contributed to the links between metabolic measures and later disease. The findings may not apply to people who already had one of these diseases at enrollment.
- Cardiovascular disease
- Type 2 diabetes
- Metabolic dysfunction-associated steatotic liver disease
- Cardiovascular-liver-metabolic multimorbidity
- Estimated glucose disposal rate
- Humans
The paper
Qilong Zhai, Shasha Guo, Jialu Sun et al.
Frontiers in Nutrition, Nov 16, 2026, CC BY, Accepted, not yet published




Comments
Be the first to comment.